West Pharmaceutical Services, I – Consensus Indicates Potential 21.8% Upside
West Pharmaceutical Services, I with ticker code (WST) have now 6 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 449 and 330 calculating the mean target price we have 383.17. Given that the stocks previous close was at 314.68 this indicates there is a potential upside of 21.8%. There is a 50 day moving average of 315.27 and the 200 day MA is 365.74. The market capitalisation for the company is $22,494m. Find out more information at: https:||www.westpharma.com [stock_market_widget type="chart" template="basic" color="green" assets="WST" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $27,389m based on the market concensus. West Pharmaceutical Services designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
West Pharmaceutical Services, I – Consensus Indicates Potential 21.8% Upside
West Pharmaceutical Services, I with ticker code (WST) have now 6 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 449 and 330 calculating the mean target price we have 383.17. Given that the stocks previous close was at 314.68 this indicates there is a potential upside of 21.8%. There is a 50 day moving average of 315.27 and the 200 day MA is 365.74. The market capitalisation for the company is $22,494m. Find out more information at: https:||www.westpharma.com [stock_market_widget type="chart" template="basic" color="green" assets="WST" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $27,389m based on the market concensus. West Pharmaceutical Services designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.